news – Caldera Health Care

Clinical Study 3 Started In October 2017

Jonathan Thompson-Bean — Thu, 30 Nov 2017 01:20:56 +0000

This pivotal study is designed to test the accuracy of the gene signatures from CS2b generated on prostate tissue in urine, allowing for the development of a highly accurate prostate cancer screening test that utilises the non-invasive sample source of urine. In total, Caldera will recruit a minimum of 300 donors who will donate matched urine and biopsy tissue samples.

The post Clinical Study 3 Started In October 2017 appeared first on Caldera Health Care.

Caldera Annual General Meeting

Jonathan Thompson-Bean — Thu, 30 Nov 2017 01:20:16 +0000

Caldera Health will hold its Annual General meeting at the end of November to update shareholders of the considerable progress made in the last 12 months including the successful completion of Clinical Study 2b confirming world class accuracy in tissue samples, and the start of Clinical Study 3.

The post Caldera Annual General Meeting appeared first on Caldera Health Care.

Caldera Participating in TIKI

Jonathan Thompson-Bean — Mon, 27 Nov 2017 01:22:13 +0000

Caldera will be participating in the TIKI (Technology Innovation and Knowledge Interchange) Tour hosted by the Ministry of Health in Wellington at the end of November in partnership with CMDT and MedTech CoRE. This is an innovation showcase to highlight the latest in healthcare technologies & research, and facilitate discussions with companies and researchers. The TIKI Tour is an great opportunity to showcase the NZ medtech landscape.

The post Caldera Participating in TIKI appeared first on Caldera Health Care.

Update of Caldera’s Development, Dr. Keith Hudson

Jonathan Thompson-Bean — Fri, 13 Oct 2017 01:23:38 +0000

Dr Keith Hudson, Director of Research and Development presented an update of Caldera’s development and an overview of the current clinical study at the Urological Society of Australia and New Zealand (USANZ) Conference in Tauranga. USANZ is the peak professional body for urological surgeons in Australia and New Zealand and the conference focussed on the latest trends and developments in urology, including a focus on the use of biomarkers in prostate diagnosis.

The post Update of Caldera’s Development, Dr. Keith Hudson appeared first on Caldera Health Care.

Rob Mitchell Presented at NZBIO

Jonathan Thompson-Bean — Thu, 12 Oct 2017 15:00:44 +0000

Rob Mitchell, Caldera Health CEO, presented at NZBIO as part of a session panel focussing on the NZ Medical Diagnostic start-up companies. The conference was an excellent opportunity to update the New Zealand bioscience community on Caldera’s progress and connect with local and international delegates across numerous biotech fields.

The post Rob Mitchell Presented at NZBIO appeared first on Caldera Health Care.

Caldera Health has expanded its commercial team

Jonathan Thompson-Bean — Wed, 01 Feb 2017 12:00:16 +0000

Caldera Health has expanded its commercial team with the appointment of Jennifer (Jen) Barnes as the head of Business Development to drive commercialisation of their prostate cancer biomarker assays. Jen is an experienced molecular diagnostics specialist, with over 15 years of experience in the clinical diagnostics field. She spent 12 years with Roche Diagnostics New Zealand, the last 6 as the Manager of Molecular and Tissue Diagnostics. She has also gained experience in health commercialisation as a business development manager at Auckland UniServices LTD, and is a co-founder in an early stage DNA biosensor company, Spot Check Technologies Ltd. Jen is a trained molecular biologist who started her career in research and clinical diagnostics. Her experience in both the science and commercial realms means she is adept at providing expert advice to support the commercialisation of life science and diagnostic opportunities.

The post Caldera Health has expanded its commercial team appeared first on Caldera Health Care.